Trial Outcomes & Findings for A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT NCT02366143)

Last Updated: 2021-09-23

Results Overview

Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1202 participants

Primary outcome timeframe

Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)

Results posted on

2021-09-23

Participant Flow

Participant milestones

Participant milestones
Measure	Arm C Bevacizumab+Paclitaxel+Carboplatin	Arm B Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin	Arm A Atezolizumab+Paclitaxel+Carboplatin
Overall Study STARTED	400	400	402
Overall Study COMPLETED	0	0	0
Overall Study NOT COMPLETED	400	400	402

Reasons for withdrawal

Reasons for withdrawal
Measure	Arm C Bevacizumab+Paclitaxel+Carboplatin	Arm B Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin	Arm A Atezolizumab+Paclitaxel+Carboplatin
Overall Study Death	307	278	280
Overall Study Lost to Follow-up	2	4	2
Overall Study Physician Decision	1	2	1
Overall Study Protocol Violation	0	0	2
Overall Study Withdrawal by Subject	16	17	22
Overall Study Sponsor request to withdraw/discontinue patient	0	6	0
Overall Study Increased Microscopic RBCS on Urinalysis	0	1	0
Overall Study Randomization Error	1	0	0
Overall Study PI Move and Site Closure	1	0	1
Overall Study Study Terminated By Sponsor	0	0	2
Overall Study Sponsor request to withdraw/discontinue patient in survival follow up	70	57	52
Overall Study Patient moved to roll-over study	1	19	28
Overall Study Patient moved to commercial stock	0	0	1
Overall Study Patient stopped treatment due to disease progression;didn't enter follow up due to study termination	0	0	1
Overall Study Patient rolling over to patient assistance program	0	0	1
Overall Study Patient continue same treatment via Post Trial Access Progarm (PTAP)	0	0	1
Overall Study Requester's instructions	1	1	1
Overall Study Uneligible	0	1	0
Overall Study Post Trial Migration	0	1	0
Overall Study Patient moving onto PTAP commercial stock	0	1	0
Overall Study Patient switched to PTAP	0	1	0
Overall Study Patient moved to commercial atezolizumab use	0	11	7

Baseline Characteristics

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Arm C n=400 Participants Bevacizumab+Paclitaxel+Carboplatin	Arm B n=400 Participants Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin	Arm A n=402 Participants Atezolizumab+Paclitaxel+Carboplatin	Total n=1202 Participants Total of all reporting groups
Age, Continuous	63.1 Years STANDARD_DEVIATION 9.3 • n=5 Participants	63.0 Years STANDARD_DEVIATION 9.5 • n=7 Participants	62.3 Years STANDARD_DEVIATION 9.2 • n=5 Participants	62.8 Years STANDARD_DEVIATION 9.3 • n=4 Participants
Sex: Female, Male Female	161 Participants n=5 Participants	160 Participants n=7 Participants	161 Participants n=5 Participants	482 Participants n=4 Participants
Sex: Female, Male Male	239 Participants n=5 Participants	240 Participants n=7 Participants	241 Participants n=5 Participants	720 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants
Race (NIH/OMB) Asian	46 Participants n=5 Participants	56 Participants n=7 Participants	48 Participants n=5 Participants	150 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Black or African American	12 Participants n=5 Participants	3 Participants n=7 Participants	9 Participants n=5 Participants	24 Participants n=4 Participants
Race (NIH/OMB) White	335 Participants n=5 Participants	322 Participants n=7 Participants	331 Participants n=5 Participants	988 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	7 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	6 Participants n=5 Participants	13 Participants n=7 Participants	10 Participants n=5 Participants	29 Participants n=4 Participants

PRIMARY outcome

Timeframe: Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)

Population: Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=356 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=336 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population Teff-high WT Population	11.3 Months Interval 9.1 to 13.0	6.8 Months Interval 5.9 to 7.4	—
Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population ITT-WT Population	8.3 Months Interval 7.7 to 9.8	6.8 Months Interval 6.0 to 7.1	—

PRIMARY outcome

Timeframe: Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)

Population: ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.

Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=359 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=337 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population	19.2 Months Interval 17.0 to 23.8	14.7 Months Interval 13.3 to 16.9	—

PRIMARY outcome

Timeframe: Baseline until death (up approximately 53 months)

Population: ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.

Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=350 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=338 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population	19.0 Months Interval 15.7 to 21.5	14.7 Months Interval 12.9 to 17.1	—

SECONDARY outcome

Timeframe: Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)

PFS, as determined by the independent review facility (IRF) Using RECIST v1.1 in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=356 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=336 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
PFS, as Determined by the Independent Review Facility (IRF) in Arm B Versus Arm C in Teff-High-WT Population and ITT-WT Population Teff-high WT Population	10.7 Months Interval 8.4 to 13.0	7.0 Months Interval 6.1 to 8.1	—
PFS, as Determined by the Independent Review Facility (IRF) in Arm B Versus Arm C in Teff-High-WT Population and ITT-WT Population ITT-WT Population	8.5 Months Interval 7.7 to 9.7	7.0 Months Interval 6.3 to 8.0	—

SECONDARY outcome

Timeframe: Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)

Population: Teff-high population is defined as the patients in the ITT population with Teff signature expression \>=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.

PFS, as determined by the investigator according to RECIST v1.1, in Arm B versus C in the Teff high population and ITT population.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=400 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=400 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population Teff-high Population	11.3 Months Interval 9.1 to 13.0	6.8 Months Interval 5.8 to 7.3	—
PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population ITT Population	8.3 Months Interval 7.9 to 9.8	6.8 Months Interval 6.0 to 7.1	—

SECONDARY outcome

Timeframe: Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)

PFS, as determined by the investigator according to RECIST v1.1, in Arm A versus B in the Teff high-WT population and ITT-WT population.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=348 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=356 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population Teff-high WT	6.3 Months Interval 5.6 to 7.8	11.3 Months Interval 9.1 to 13.0	—
PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population ITT-WT	6.3 Months Interval 5.6 to 7.0	8.3 Months Interval 7.7 to 9.8	—

SECONDARY outcome

Timeframe: Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)

Population: The PD-L1-selected WT populations are defined as the PD-L1-selected populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with a sensitizing EGFR mutation or ALK translocation.

PFS as Determined by the Investigator according to RECIST v1.1, in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=190 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=164 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup TC2/3 or IC2/3 Subgroup	11.1 Months Interval 8.3 to 13.0	6.8 Months Interval 5.8 to 7.7	—
PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup TC1/2/3 or IC1/2/3 Subgroup	11.0 Months Interval 8.3 to 12.5	6.8 Months Interval 5.8 to 7.3	—

SECONDARY outcome

Timeframe: Baseline until death (up to approximately 34 months)

OS in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=192 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=165 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
OS in Arm B Versus Arm C by PD-L1 Subgroup TC 2/3 or IC2/3 Population	22.2 Months Interval 17.0 to 26.1	16.7 Months Interval 10.5 to 24.2	—
OS in Arm B Versus Arm C by PD-L1 Subgroup TC1/2/3 or IC1/2/3 Population	22.5 Months Interval 18.2 to 26.1	16.4 Months Interval 11.2 to 22.9	—

SECONDARY outcome

Timeframe: Baseline until death (up approximately 53 months)

Population: PD-L1 WT populations are defined as the PD-L1 populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with an activating EGFR mutation or ALK translocation.

OS in Arm A Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=185 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=165 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
OS in Arm A Versus Arm C by PD-L1 Subgroup TC2/3 or IC2/3 Population	26.1 Months Interval 20.5 to 40.0	17.0 Months Interval 10.3 to 22.9	—
OS in Arm A Versus Arm C by PD-L1 Subgroup TC1/2/3 or IC1/2/3 Population	24.4 Months Interval 20.2 to 28.1	16.0 Months Interval 11.2 to 20.1	—

SECONDARY outcome

Timeframe: Baseline until death (up to approximately 34 months)

Population: Teff-high WT population, defined as the Teff-high population excluding patients with activating EGFR mutation or ALK translocation. Teff-high population, defined as participants in the ITT population with Teff signature expression \>=-1.91. ITT population, defined as all randomized patients, regardless of receipt of the assigned treatment.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=400 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=400 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population Teff High-WT Population	25.0 Months Interval 17.8 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	16.7 Months Interval 12.4 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	—
OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population Teff High Population	25.2 Months Interval 19.1 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	16.7 Months Interval 12.4 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	—
OS in Arm B Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population ITT Population	19.8 Months Interval 17.4 to 24.2	14.9 Months Interval 13.4 to 17.1	—

SECONDARY outcome

Timeframe: Baseline until death (up approximately 53 months)

Population: Teff-high WT population, defined as Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. Teff-high population, defined as patients in the ITT population with Teff signature expression \>=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=402 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=400 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population Teff-high WT Population	21.3 Months Interval 17.6 to 26.3	16.3 Months Interval 11.2 to 22.3	—
OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population Teff-high Population	21.0 Months Interval 17.1 to 26.0	16.7 Months Interval 11.4 to 21.6	—
OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population ITT Population	19.0 Months Interval 16.3 to 21.5	15.0 Months Interval 13.4 to 17.1	—

SECONDARY outcome

Timeframe: Baseline until death (up approximately 53 months)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=350 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=359 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
OS in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population ITT-WT Population	19.0 Months Interval 15.7 to 21.5	19.5 Months Interval 17.0 to 22.2	—
OS in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population Teff High-WT Population	21.3 Months Interval 17.6 to 26.3	25.8 Months Interval 19.1 to 32.6	—

SECONDARY outcome

Timeframe: Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)

DOR, as determined by investigator according to RECIST v1.1 in Arm B versus Arm C in the Teff high-WT population and the ITT-WT population.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=224 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=159 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Duration of Response (DOR), as Determined By Investigator in Arm B Versus Arm C Teff high-WT Population	11.2 Months Interval 9.7 to 15.7	5.7 Months Interval 4.9 to 7.0	—
Duration of Response (DOR), as Determined By Investigator in Arm B Versus Arm C ITT-WT Population	9.0 Months Interval 6.9 to 11.4	5.7 Months Interval 5.1 to 6.5	—

SECONDARY outcome

Timeframe: Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)

Percentage of Participants With an Objective Response (OR) (Complete Response \[CR\] or Partial Response \[PR\]) as Determined by the Investigator using RECIST v1.1 in the Teff-High-WT population and ITT-WT population.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=347 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=353 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=331 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population Teff-high WT Population	54.0 Percentage	69.3 Percentage	53.5 Percentage
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator in the Teff-High-WT Population and ITT-WT Population ITT-WT Population	49.3 Percentage	63.5 Percentage	48.0 Percentage

SECONDARY outcome

Timeframe: Baseline to 2 years or death, whichever occurs first.

OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=235 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=196 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
OS Rates at Years 1 and 2 in Arm B Versus Arm C 2-Year ITT-WT Population	43.42 Percentage Interval 36.94 to 49.9	33.71 Percentage Interval 27.44 to 39.98	—
OS Rates at Years 1 and 2 in Arm B Versus Arm C 1-Year Teff-high WT Population	68.63 Percentage Interval 61.28 to 75.98	58.74 Percentage Interval 50.03 to 67.45	—
OS Rates at Years 1 and 2 in Arm B Versus Arm C 1-Year ITT-WT Population	67.32 Percentage Interval 62.41 to 72.22	60.63 Percentage Interval 55.34 to 65.93	—
OS Rates at Years 1 and 2 in Arm B Versus Arm C 2-Year Teff-high WT Population	52.03 Percentage Interval 43.12 to 60.94	41.70 Percentage Interval 31.55 to 51.85	—

SECONDARY outcome

Timeframe: Baseline to 2 years or death, whichever occurs first.

OS at 1- and 2-year landmark timepoints in Teff-high WT population and ITT-WT population.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=222 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=197 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
OS Rates at Years 1 and 2 in Arm A Versus Arm C 1-Year Teff-high WT Population	67.48 Percentage Interval 60.29 to 74.68	56.92 Percentage Interval 48.32 to 65.53	—
OS Rates at Years 1 and 2 in Arm A Versus Arm C 2-Year Teff-high WT Population	46.01 Percentage Interval 38.36 to 53.66	38.74 Percentage Interval 30.26 to 47.22	—
OS Rates at Years 1 and 2 in Arm A Versus Arm C 1-Year ITT-WT Population	64.06 Percentage Interval 59.02 to 69.11	59.89 Percentage Interval 54.61 to 65.17	—
OS Rates at Years 1 and 2 in Arm A Versus Arm C 2-Year ITT-WT Population	41.45 Percentage Interval 36.26 to 46.64	31.79 Percentage Interval 26.75 to 36.82	—

SECONDARY outcome

Timeframe: Baseline up to approximately 29 months

EORTC QLQ-C30 is a validated \& reliable self-report measure (Aaronson et al.1993;Fitzsimmons et al.1999) that consists of 30 questions that assess 5 aspects of patient functioning (physical,emotional,role, cognitive,and social), 3 symptom scales (fatigue,nausea \& vomiting, pain),global health/quality of life,and six single items (dyspnea,insomnia, appetite loss,constipation,diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life);however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al.1998).

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=348 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=356 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=336 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score Dyspnea in Teff-high WT Population	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score Dyspnea in ITT-WT Population	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.

SECONDARY outcome

Timeframe: Baseline up to approximately 29 months

QLQ-LC13 Quality-of-Life Questionnaire Lung Cancer Module incorporates one multiple-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=348 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=356 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=336 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Cough in Teff-high WT Population	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Interval 21.0 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Dyspnea in Teff-high WT Population	NA Months Interval 5.6 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Interval 6.3 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Chest Pain in Teff-high WT Population	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	22.2 Months Interval 22.2 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	18.4 Months Interval 18.4 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Arm and/or Shoulder Pain in Teff-high WT	NA Months Interval 18.3 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	19.5 Months Interval 12.5 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Interval 12.7 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Cough in ITT-WT Population	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Interval 21.0 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Dyspnea in ITT-WT Population	21.9 Months Interval 9.7 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Interval 10.0 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Arm and/or Shoulder Pain in ITT-WT	NA Months Interval 18.3 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	19.5 Months Interval 15.2 to Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.
TTD in Patient-Reported Lung Cancer Symptoms as Determined by EORTC Quality-of-Life Questionnaire-Core Lung Cancer Module 13 (QLQ-LC13) Score Pain in Chest in ITT-WT Population	NA Months Value is not available due to an insufficient number of participants with the event. Median is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Interval 22.2 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.	NA Months Interval 18.4 to Value is not available due to an insufficient number of participants with the event. Upper confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.

SECONDARY outcome

Timeframe: Baseline up to approximately 29 months

Population: No participants were analyzed due to psychometric properties within the NSCLC population are still being determined. Due to quality issues data not analyzed.

The SILC (Symptoms in Lung Cancer) scale was used to assess patient-reported severity of lung cancer symptoms (chest pain, dyspnea, and cough). The SILC scale is a 9-item content validated self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, and chest pain with a symptom severity score. The SILC questionnaire comprises three individual symptoms (dyspnea, cough, chest pain) and are scored at the individual symptom level, thus have a dyspnea score, chest pain score, and cough score. Each individual symptom score is calculated as the average of responses for the symptom items \[e.g. Chest Pain Score=mean (item 1; item 2)\]. An increase in score is suggestive of a worsening in symptomology (i.e. frequency or severity). A score change of ≥0.3 points for the dyspnea and cough symptom scores is considered to be clinically significant; whereas a score change of ≥0.5 points for the chest pain score is considered to be clinically significant.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to data cutoff date 7 December 2020 (up to approximately 68 months)

Population: Safety population included all treated patients, defined as randomized patients who received any amount of any component of study treatment.

Percentage of participants with at least one adverse event.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=394 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=393 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=400 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Percentage of Participants With Adverse Events	99.0 Percentage	98.2 Percentage	97.8 Percentage

SECONDARY outcome

Timeframe: Baseline up to approximately 29 months

Population: The baseline ADA-evaluable population for each study treatment included patients who had a baseline ADA result. The post-baseline ADA-evaluable population for each study treatment included patients who had at least one post-baseline ADA result and had received at least on dose of that study treatment.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=389 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=376 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab	4.6 Percentage of Participants	2.9 Percentage of Participants	—

SECONDARY outcome

Timeframe: Day 1 of Cycle 1 and 3 (Cycle length=21 days)

Population: The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.

The predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=378 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=364 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Arm A and Arm B Cycle 1 Day 1	410 mcg/mL Standard Deviation 157	414 mcg/mL Standard Deviation 127	—
Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Arm A and Arm B Cycle 3 Day 1	498 mcg/mL Standard Deviation 160	540 mcg/mL Standard Deviation 198	—

SECONDARY outcome

Timeframe: Day 21 of Cycles 1, 2 3, and 7 (Cycle length=21 days)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=354 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=345 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B Cycle 1 Day 21	76.4 mcg/mL Standard Deviation 37.7	80.8 mcg/mL Standard Deviation 41.4	—
Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B Cycle 2 Day 21	119 mcg/mL Standard Deviation 55.7	130 mcg/mL Standard Deviation 57.1	—
Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B Cycle 3 Day 21	146 mcg/mL Standard Deviation 58.9	160 mcg/mL Standard Deviation 102	—
Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Arm A and Arm B Cycle 7 Day 21	219 mcg/mL Standard Deviation 89.6	220 mcg/mL Standard Deviation 99.0	—

SECONDARY outcome

Timeframe: Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 h after carboplatin infusion (infusion duration=15 to 30 minutes) on D1 of Cy1,3 (Cycle length=21 days)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=28 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=35 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=24 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C Cy3D1 Before End of Infusion	20900 ng/mL Standard Deviation 8330	18700 ng/mL Standard Deviation 9410	20600 ng/mL Standard Deviation 12900
Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C Cy1D1 Pre-dose	NA ng/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Carboplatin.	NA ng/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Carboplatin.	NA ng/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Carboplatin.
Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C Cy1D1 Before End of Infusion	18300 ng/mL Standard Deviation 9610	18300 ng/mL Standard Deviation 11900	17200 ng/mL Standard Deviation 9860
Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C Cy1D1 After Infusion	11700 ng/mL Standard Deviation 5570	13900 ng/mL Standard Deviation 14300	10100 ng/mL Standard Deviation 5320
Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C Cy2D21	176 ng/mL Standard Deviation 82.9	190 ng/mL Standard Deviation 113	143 ng/mL Standard Deviation 73.0
Plasma Concentrations for Carboplatin in Arm A, Arm B, and Arm C Cy3D1 After Infusion	11700 ng/mL Standard Deviation 6990	12200 ng/mL Standard Deviation 7480	10400 ng/mL Standard Deviation 4150

SECONDARY outcome

Timeframe: Predose (same day of treatment administration), 5-10 minutes before end of paclitaxel infusion, 1 h after paclitaxel infusion (infusion duration=3 h) on D1 of Cy1,3 (Cycle length=21 days)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=28 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=35 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=24 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C Cy1D1 Pre-dose	NA ng/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Paclitaxel.	NA ng/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Paclitaxel.	NA ng/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Paclitaxel.
Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C Cy1D1 Before End of Infusion	4850 ng/mL Standard Deviation 2800	6440 ng/mL Standard Deviation 3640	5560 ng/mL Standard Deviation 2590
Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C Cy1D1 After Infusion	2300 ng/mL Standard Deviation 2790	2490 ng/mL Standard Deviation 3020	1980 ng/mL Standard Deviation 1780
Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C Cy2D21	NA ng/mL Standard Deviation NA Mean or SD is not reported because more than half of the samples at the specified timepoint are below the limit of quantification.	NA ng/mL Standard Deviation NA Mean or SD is not reported because more than half of the samples at the specified timepoint are below the limit of quantification.	—
Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C Cy3D1 Before End Of Infusion	5810 ng/mL Standard Deviation 3610	7810 ng/mL Standard Deviation 4510	7810 ng/mL Standard Deviation 5160
Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C Cy3D1 After Infusion	1800 ng/mL Standard Deviation 1660	2990 ng/mL Standard Deviation 5830	1930 ng/mL Standard Deviation 1380

SECONDARY outcome

Timeframe: Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length=21 days)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=205 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=215 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Cmax of Bevacizumab in Arm B and Arm C Cycle 1 Day 1	329 mcg/mL Standard Deviation 129	323 mcg/mL Standard Deviation 95.0	—
Cmax of Bevacizumab in Arm B and Arm C Cycle 3 Day 1	413 mcg/mL Standard Deviation 126	430 mcg/mL Standard Deviation 123	—

SECONDARY outcome

Timeframe: Cycle 1 Day 1 and Cycle 2 Day 21 (Cycle length=21 days)

Outcome measures

Outcome measures
Measure	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) n=325 Participants Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) n=348 Participants Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.	Arm C (Bevacizumab+Paclitaxel+Carboplatin) Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Cmin of Bevacizumab in Arm B and Arm C Cycle 1 Day 1	NA mcg/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Bevacizumab.	NA mcg/mL Standard Deviation NA Predose of Cycle 1 Day 1 administration of Bevacizumab.	—
Cmin of Bevacizumab in Arm B and Arm C Cycle 2 Day 21	98.0 mcg/mL Standard Deviation 50.9	90.4 mcg/mL Standard Deviation 36.8	—

Adverse Events

Arm C (Bev+CP)

Serious events: 142 serious events

Other events: 381 other events

Deaths: 311 deaths

Arm B (Atezo+Bev+CP)

Serious events: 190 serious events

Other events: 375 other events

Deaths: 285 deaths

Arm A (Atezo+CP)

Serious events: 170 serious events

Other events: 385 other events

Deaths: 293 deaths

Serious adverse events

Other adverse events

Additional Information

Medical Communications

Hoffmann-La Roche

Phone: 800-821-8590

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER